I wouldnt expect on-going Attrius sales to be PR'd as they are part of the cycle now. The only time we will here about them is in the Q's or when they are officially marketed/adapted for anything beyond cardiac.
Pat always said the Attrius sales will help fund the growth of the company. PosiRX is that evolution in growth.
I fully agree that Attrius sales need to be published. Because the asking price is known, the publication of sales comes as close to publishing revenue without actually publishing it, and the bottom line with any company is $$; not product development; not the introductions of new products; not trade shows. Show me the money.